SBC Medical Group (NASDAQ:SBC – Free Report) had its target price raised by BTIG Research from $8.00 to $10.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.
Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of SBC Medical Group from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings upgraded SBC Medical Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.
Check Out Our Latest Analysis on SBC
SBC Medical Group Price Performance
SBC Medical Group stock opened at $7.35 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.27 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $5.13 and a 200 day moving average price of $3.98. SBC Medical Group has a 12-month low of $2.78 and a 12-month high of $7.39. The stock has a market cap of $755.93 million, a P/E ratio of 14.70, a PEG ratio of 3.30 and a beta of 0.52.
SBC Medical Group (NASDAQ:SBC – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.03. SBC Medical Group had a net margin of 27.26% and a return on equity of 19.14%. The company had revenue of $58.58 million for the quarter, compared to analyst estimates of $48.90 million. Sell-side analysts anticipate that SBC Medical Group will post 0.44 earnings per share for the current year.
Institutional Trading of SBC Medical Group
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC purchased a new stake in SBC Medical Group in the 3rd quarter valued at about $36,000. Bank of New York Mellon Corp acquired a new position in SBC Medical Group in the first quarter valued at about $43,000. Bank of America Corp DE purchased a new position in SBC Medical Group during the second quarter worth about $35,000. Williams & Novak LLC boosted its stake in SBC Medical Group by 31.2% during the second quarter. Williams & Novak LLC now owns 18,686 shares of the company’s stock worth $58,000 after buying an additional 4,449 shares during the period. Finally, Deutsche Bank AG purchased a new position in SBC Medical Group during the second quarter worth about $58,000. 60.82% of the stock is owned by institutional investors and hedge funds.
SBC Medical Group Company Profile
SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.
See Also
- Five stocks we like better than SBC Medical Group
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
